drugset
drugset / Trial / NCT04911959

Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC

NCT04911959 ↗

Phase 1/2 Unknown 50 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

single-center clinical trial studies have verified the safety and effectiveness of transcatheter arterial chemoembolization (TACE) combined with lenvatinib in preventing postoperative recurrence of microvascular invasion (MVI) positive HCC patients. Explore a new clinical first-line treatment plan for patients with liver cancer microvascular invasion after surgery.

Timeline

Start
2022-07-01
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral

Indications

hepatocellular carcinoma